Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften E-learning Web-tv Video Audio
Tips voor Mijn BSL
UITGEBREID ZOEKEN
Inloggen
Top
Quality of Life Research
Gepubliceerd in: Quality of Life Research 1/2019

17-09-2018

Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn’s disease

Auteurs: Fanni Rencz, Peter L. Lakatos, László Gulácsi, Valentin Brodszky, Zsuzsanna Kürti, Szilvia Lovas, János Banai, László Herszényi, Tamás Cserni, Tamás Molnár, Márta Péntek, Károly Palatka

Gepubliceerd in: Quality of Life Research | Uitgave 1/2019

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Abstract

Purpose

The EuroQol five-dimension questionnaire (EQ-5D) is the most commonly used instrument to obtain utility values for cost-effectiveness analyses of treatments for Crohn’s disease (CD). We aimed to compare the measurement properties of the two adult versions of EQ-5D (EQ-5D-3L and EQ-5D-5L) in patients with CD.

Methods

Between 2016 and 2017, a multicentre cross-sectional survey was carried out. Consecutive outpatients with CD completed the 3L, 5L and EQ visual analogue scale (VAS). Disease severity was graded by the Crohn’s Disease Activity Index (CDAI) and Perianal Disease Activity Index (PDAI). The 3L and 5L were compared in terms of feasibility, agreement, ceiling effect, redistribution properties, discriminatory power, convergent and known-groups validity.

Results

Two-hundred and six patients (54.9% male, mean age 35 ± 11 years) participated in the survey. For 3L, 25 unique health states were observed versus 59 for the 5L. The overall ceiling effect decreased from 29.6% (3L) to 25.5% (5L). Absolute discriminatory power improved (mean Shannon index 0.84 vs. 1.18). The 3L correlated stronger with EQ VAS and CDAI scores, whereas the 5L with PDAI. The 5L demonstrated a better known-groups validity on the basis of age, perianal fistulas, extraintestinal manifestations and disability.

Conclusions

This is the first study to report the impact of CD on quality of life using the EQ-5D-5L questionnaire. The 5L seems to perform better than 3L in terms of feasibility, ceiling effect, discriminatory power and known-groups validity. Understanding the differences in psychometrics between the 3L and 5L is essential as they have substantial implications for financial decision-making about CD treatments.
vorige artikel Mapping the Alzheimer’s Disease Cooperative Study-Activities of Daily Living Inventory to the Health Utility Index Mark III
volgende artikel Psychometric performance assessment of Malay and Malaysian English version of EQ-5D-5L in the Malaysian population
Literatuur
1.
Ng, S. C., Shi, H. Y., Hamidi, N., Underwood, F. E., Tang, W., Benchimol, E. I., et al. (2018). Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. The Lancet, 390(10114), 2769–2778.
2.
Kaplan, G. G. (2015). The global burden of IBD: From 2015 to 2025. Nature Reviews Gastroenterology & Hepatology, 12(12), 720–727.
3.
Torres, J., Mehandru, S., Colombel, J. F., & Peyrin-Biroulet, L. (2017). Crohn’s disease. The Lancet, 389(10080), 1741–1755.
4.
Harbord, M., Annese, V., Vavricka, S. R., Allez, M., Barreiro-de Acosta, M., Boberg, K. M., et al. (2016). The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. Journal of Crohn’s and Colitis, 10(3), 239–254.PubMed
5.
van der Have, M., van der Aalst, K. S., Kaptein, A. A., Leenders, M., Siersema, P. D., Oldenburg, B., et al. (2014). Determinants of health-related quality of life in Crohn’s disease: A systematic review and meta-analysis. Journal of Crohn’s and Colitis, 8(2), 93–106.PubMed
6.
Brodszky, V., Rencz, F., Pentek, M., Baji, P., Lakatos, P. L., & Gulacsi, L. (2016). A budget impact model for biosimilar infliximab in Crohn’s disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia. Expert Review of Pharmacoeconomics & Outcomes Research, 16(1), 119–125.
7.
Rencz, F., Pentek, M., Bortlik, M., Zagorowicz, E., Hlavaty, T., Sliwczynski, A., et al. (2015). Biological therapy in inflammatory bowel diseases: Access in Central and Eastern Europe. World Journal of Gastroenterology, 21(6), 1728–1737.PubMedPubMedCentral
8.
Boncz, I., & Sebestyen, A. (2006). Financial deficits in the health services of the UK and Hungary. The Lancet, 368(9539), 917–918.
9.
10.
11.
12.
13.
14.
Rencz, F., Gulacsi, L., Drummond, M., Golicki, D., Prevolnik Rupel, V., Simon, J., et al. (2016). EQ-5D in central and eastern Europe: 2000–2015. Quality of Life Research, 25(11), 2693–2710.PubMed
15.
Rowen, D., Azzabi Zouraq, I., Chevrou-Severac, H., & van Hout, B. (2017). International regulations and recommendations for utility data for health technology assessment. Pharmacoeconomics, 35(Suppl 1), 11–19.PubMed
16.
Sanders, G. D., Neumann, P. J., Basu, A., Brock, D. W., Feeny, D., Krahn, M., et al. (2016). Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second panel on cost-effectiveness in health and medicine. JAMA, 316(10), 1093–1103.PubMed
17.
18.
Huoponen, S., & Blom, M. (2015). A systematic review of the cost-effectiveness of biologics for the treatment of inflammatory bowel diseases. PLoS ONE. 10(12), e0145087.PubMedPubMedCentral
19.
Pillai, N., Dusheiko, M., Burnand, B., & Pittet, V. (2017). A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease. PLoS ONE. 12(10), e0185500.PubMedPubMedCentral
20.
Rencz, F., Gulacsi, L., Pentek, M., Gecse, K. B., Dignass, A., Halfvarson, J., et al. (2017). Cost-utility of biological treatment sequences for luminal Crohn’s disease in Europe. Expert Review of Pharmacoeconomics & Outcomes Research, 17(6), 597–606.
21.
Punekar, Y. S., Sunderland, T., Hawkins, N., & Lindsay, J. (2010). Cost-effectiveness of scheduled maintenance treatment with infliximab for pediatric Crohn’s disease. Value in Health, 13(2), 188–195.PubMed
22.
Baji, P., Gulácsi, L., Brodszky, V., Végh, Z., Danese, S., Irving, P. M., et al. (2018). Cost-effectiveness of biological treatment sequences for fistulising Crohn’s disease across Europe. United European Gastroenterology Journal, 6(2), 310–321.PubMedPubMedCentral
23.
Malinowski, K. P., & Kawalec, P. (2016). Health utility of patients with Crohn’s disease and ulcerative colitis: A systematic review and meta-analysis. Expert Review of Pharmacoeconomics & Outcomes Research, 16(4), 441–453.
24.
Brooks, R. (2012). The EuroQol group after 25 years. New York: Springer.
25.
Konig, H. H., Ulshofer, A., Gregor, M., von Tirpitz, C., Reinshagen, M., Adler, G., et al. (2002). Validation of the EuroQol questionnaire in patients with inflammatory bowel disease. European Journal of Gastroenterology & Hepatology, 14(11), 1205–1215.
26.
Stark, R. G., Reitmeir, P., Leidl, R., & Konig, H. H. (2010). Validity, reliability, and responsiveness of the EQ-5D in inflammatory bowel disease in Germany. Inflammatory Bowel Disease, 16(1), 42–51.
27.
Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., et al. (2011). Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research, 20(10), 1727–1736.PubMedPubMedCentral
28.
Janssen, M. F., Pickard, A. S., Golicki, D., Gudex, C., Niewada, M., Scalone, L., et al. (2013). Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: A multi-country study. Quality of Life Research, 22(7), 1717–1727.PubMed
29.
Buchholz, I., Janssen, M. F., Kohlmann, T., & Feng, Y. S. (2018). A systematic review of studies comparing the measurement properties of the three-level and five-level versions of the EQ-5D. Pharmacoeconomics, 36(6), 645–661.PubMedPubMedCentral
30.
Norton, C., Dibley, L. B., Hart, A., Duncan, J., Emmanuel, A., Knowles, C. H., et al. (2015). Faecal incontinence intervention study (FINS): Self-management booklet information with or without nurse support to improve continence in people with inflammatory bowel disease: Study protocol for a randomized controlled trial. Trials, 16, 444.PubMedPubMedCentral
31.
Tew, G. A., Carpenter, R., Seed, M., Anderson, S., Langmead, L., Fairhurst, C., et al. (2017). Feasibility of high-intensity interval training and moderate-intensity continuous training in adults with inactive or mildly active Crohn’s disease: Study protocol for a randomised controlled trial. Pilot and Feasibility Studies, 3, 17.PubMedPubMedCentral
32.
Pentek, M., Lakatos, P. L., Oorsprong, T., Gulacsi, L., Pavlova, M., Groot, W., et al. (2017). Access to biologicals in Crohn’s disease in ten European countries. World Journal of Gastroenterology, 23(34), 6294–6305.PubMedPubMedCentral
33.
EuroQol, G. (1990). EuroQol–a new facility for the measurement of health-related quality of life. Health Policy, 16(3), 199–208.
34.
Brooks, R. (1996). EuroQol: The current state of play. Health Policy, 37(1), 53–72.PubMed
35.
Poor, A. K., Rencz, F., Brodszky, V., Gulacsi, L., Beretzky, Z., Hidvegi, B., et al. (2017). Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients. Quality of Life Research, 26(12), 3409–3419.PubMed
36.
Janssen, M. F., Birnie, E., Haagsma, J. A., & Bonsel, G. J. (2008). Comparing the standard EQ-5D three-level system with a five-level version. Value in Health, 11(2), 275–284.PubMed
37.
van Hout, B., Janssen, M. F., Feng, Y. S., Kohlmann, T., Busschbach, J., Golicki, D., et al. (2012). Interim scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L value sets. Value in Health, 15(5), 708–715.PubMed
38.
Dolan, P. (1997). Modeling valuations for EuroQol health states. Medical Care, 35(11), 1095–1108.PubMed
39.
Devlin, N. J., Shah, K. K., Feng, Y., Mulhern, B., & van Hout, B. (2018). Valuing health-related quality of life: An EQ-5D-5L value set for England. Health Economics, 27(1), 7–22.PubMed
40.
Winship, D. H., Summers, R. W., Singleton, J. W., Best, W. R., Becktel, J. M., Lenk, L. F., et al. (1979). National Cooperative Crohn’s Disease Study: Study design and conduct of the study. Gastroenterology, 77(4 Pt 2), 829–842.PubMed
41.
Sandborn, W. J., Feagan, B. G., Hanauer, S. B., Lochs, H., Lofberg, R., Modigliani, R., et al. (2002). A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology, 122(2), 512–530.PubMed
42.
Irvine, E. J. (1995). Usual therapy improves perianal Crohn’s disease as measured by a new disease activity index. McMaster IBD Study Group. Journal of Clinical Gastroenterology, 20(1), 27–32.PubMed
43.
Losco, A., Vigano, C., Conte, D., Cesana, B. M., & Basilisco, G. (2009). Assessing the activity of perianal Crohn’s disease: Comparison of clinical indices and computer-assisted anal ultrasound. Inflammatory Bowel Disease, 15(5), 742–749.
44.
Ripamonti, C. I. (2012). Pain management. Annals of Oncology, 23(Suppl 10), 294–301.
45.
Janssen, M. F., Birnie, E., & Bonsel, G. J. (2008). Quantification of the level descriptors for the standard EQ-5D three-level system and a five-level version according to two methods. Quality of Life Research, 17(3), 463–473.PubMedPubMedCentral
46.
Pickard, A. S., De Leon, M. C., Kohlmann, T., Cella, D., & Rosenbloom, S. (2007). Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients. Medical Care, 45(3), 259–263.PubMed
47.
Buchholz, I., Thielker, K., Feng, Y. S., Kupatz, P., & Kohlmann, T. (2015). Measuring changes in health over time using the EQ-5D 3L and 5L: A head-to-head comparison of measurement properties and sensitivity to change in a German inpatient rehabilitation sample. Quality of Life Research, 24(4), 829–835.PubMed
48.
Shrout, P. E., & Fleiss, J. L. (1979). Intraclass correlations: Uses in assessing rater reliability. Psychological Bulletin, 86(2), 420–428.PubMed
49.
Cicchetti, D. (1994). Guidelines, criteria, and rules of thumb for evaluating normed and standardized assessment instruments in psychology. Psychological Assessment, 6(4), 284–290.
50.
Bland, J. M., & Altman, D. G. (1986). Statistical methods for assessing agreement between two methods of clinical measurement. The Lancet, 1(8476), 307–310.
51.
Shannon, C. E. (1948). The mathematical theory of communication. The Bell System Technical Journal, 27, 379–423.
52.
Shannon, C. E., & Weaver, W. (1949). The mathematical theory of communication. Urbana: University of Illinois Press, pp. 104–107.
53.
Swinscow, T., & Campbell, M. (2002). Statistics at square one. London: BMJ.
54.
Ferreira, L. N., Ferreira, P. L., Ribeiro, F. P., & Pereira, L. N. (2016). Comparing the performance of the EQ-5D-3L and the EQ-5D-5L in young Portuguese adults. Health and Quality of Life Outcomes, 14(1), 89.PubMedPubMedCentral
55.
Yfantopoulos, J., Chantzaras, A., & Kontodimas, S. (2017). Assessment of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in psoriasis. Archives of Dermatological Research, 309(5), 357–370.PubMed
56.
Scalone, L., Ciampichini, R., Fagiuoli, S., Gardini, I., Fusco, F., Gaeta, L., et al. (2013). Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases. Quality of Life Research, 22(7), 1707–1716.PubMed
57.
Jia, Y. X., Cui, F. Q., Li, L., Zhang, D. L., Zhang, G. M., Wang, F. Z., et al. (2014). Comparison between the EQ-5D-5L and the EQ-5D-3L in patients with hepatitis B. Quality of Life Research, 23(8), 2355–2363.PubMed
58.
Pan, C. W., Sun, H. P., Wang, X., Ma, Q., Xu, Y., Luo, N., et al. (2015). The EQ-5D-5L index score is more discriminative than the EQ-5D-3L index score in diabetes patients. Quality of Life Research, 24(7), 1767–1774.PubMed
59.
Kim, S. H., Kim, H. J., Lee, S. I., & Jo, M. W. (2012). Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L in cancer patients in Korea. Quality of Life Research, 21(6), 1065–1073.PubMed
60.
Golicki, D., Niewada, M., Karlinska, A., Buczek, J., Kobayashi, A., Janssen, M. F., et al. (2015). Comparing responsiveness of the EQ-5D-5L, EQ-5D-3L and EQ VAS in stroke patients. Quality of Life Research, 24(6), 1555–1563.PubMed
61.
Greene, M. E., Rader, K. A., Garellick, G., Malchau, H., Freiberg, A. A., & Rolfson, O. (2015). The EQ-5D-5L improves on the EQ-5D-3L for health-related quality-of-life assessment in patients undergoing total hip arthroplasty. Clinical Orthopaedics and Related Research, 473(11), 3383–3390.PubMed
62.
Buxton, M. J., Lacey, L. A., Feagan, B. G., Niecko, T., Miller, D. W., & Townsend, R. J. (2007). Mapping from disease-specific measures to utility: An analysis of the relationships between the Inflammatory Bowel Disease Questionnaire and Crohn’s Disease Activity Index in Crohn’s disease and measures of utility. Value in Health, 10(3), 214–220.PubMed
63.
de Dombal, F. T., & Softley, A. (1987). IOIBD report no 1: Observer variation in calculating indices of severity and activity in Crohn’s disease. International Organisation for the Study of Inflammatory Bowel Disease. Gut, 28(4), 474–481.PubMedPubMedCentral
64.
Khanna, R., Nelson, S. A., Feagan, B. G., D’Haens, G., Sandborn, W. J., Zou, G. Y., et al. (2016). Endoscopic scoring indices for evaluation of disease activity in Crohn’s disease. Cochrane Database of Systematic Reviews, 8, CD010642.
65.
Peyrin-Biroulet, L., Panes, J., Sandborn, W. J., Vermeire, S., Danese, S., Feagan, B. G., et al. (2016). Defining disease severity in inflammatory bowel diseases: Current and future directions. Clinical Gastroenterology and Hepatology, 14(3), 348–354 e317.PubMed
66.
Regueiro, M., Kip, K. E., Schraut, W., Baidoo, L., Sepulveda, A. R., Pesci, M., et al. (2011). Crohn’s disease activity index does not correlate with endoscopic recurrence one year after ileocolonic resection. Inflammatory Bowel Disease, 17(1), 118–126.
67.
Mulhern, B., Feng, Y., Shah, K., Janssen, M. F., Herdman, M., van Hout, B., et al. (2018). Comparing the UK EQ-5D-3L and english EQ-5D-5L value sets. Pharmacoeconomics, 36(6), 699–713.PubMedPubMedCentral
68.
Devlin, N., Brazier, J., Pickard, A. S., & Stolk, E. (2018). 3L, 5L, What the L? A NICE Conundrum. Pharmacoeconomics, 36(6), 637–640.PubMedPubMedCentral
69.
Hernandez Alava, M., Wailoo, A., Grimm, S., Pudney, S., Gomes, M., Sadique, Z., et al. (2018). EQ-5D-5L versus EQ-5D-3L: The Impact on Cost Effectiveness in the United Kingdom. Value in Health, 21(1), 49–56.PubMed
70.
Janssen, M. F., Bonsel, G. J., & Luo, N. (2018). Is EQ-5D-5L better than EQ-5D-3L? A head-to-head comparison of descriptive systems and value sets from seven countries. Pharmacoeconomics, 36(6), 675–697.
Metagegevens
Titel
Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn’s disease
Auteurs
Fanni Rencz
Peter L. Lakatos
László Gulácsi
Valentin Brodszky
Zsuzsanna Kürti
Szilvia Lovas
János Banai
László Herszényi
Tamás Cserni
Tamás Molnár
Márta Péntek
Károly Palatka
Publicatiedatum
17-09-2018
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 1/2019
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-018-2003-4

Andere artikelen Uitgave 1/2019

Quality of Life Research 1/2019 Naar de uitgave

OriginalPaper

Development and content validity of a hemodialysis symptom patient-reported outcome measure

OriginalPaper

Scoring the Child Health Utility 9D instrument: estimation of a Chinese child and adolescent-specific tariff

OriginalPaper

The impact of education on knowledge, adherence and quality of life among patients on haemodialysis

OriginalPaper

Primary dysmenorrhea with and without premenstrual syndrome: variation in quality of life over menstrual phases

OriginalPaper

Psychometric properties of a modified version of the Weiss Functional Impairment Rating Scale-Parent Report (WFIRS-P) in a clinical sample of children with aggressive behavior

Review

A systematic review of utility values in children with cerebral palsy